FDA accepts application for Roche's faricimab for macuolar degeneration, edema

  -- Across four phase III studies, approximately half of patients receiving

      faricimab could extend treatment time to every four months -- the first 
      time this level of durability has been achieved in phase III nAMD and DME 
      studies 
 
   -- If approved, faricimab would be the first and only medicine designed to 
      target two distinct pathways that drive retinal diseases that can cause 
      vision loss 
 
   -- The European Medicines Agency has also validated the faricimab Marketing 
      Authorisation Application submission in nAMD and DME 

https://www.marketscreener.com/quote/stock/ROCHE-HOLDING-AG-9364975/news/Press-Release-FDA-accepts-application-for-Roche-s-faricimab-for-the-treatment-of-neovascular-age-r-35996825/